Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an open-label, non-comparative, multicenter, expanded access study of RO5185426 in patients who have received prior systemic therapy for metastatic melanoma and who have no other satisfactory treatment options.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Overall Trial | Experimental | Participants received vemurafenib 960 milligram (mg) orally two times a day for up to one year. Participants were treated until disease progression, unmanageable toxicity most probably attributable to vemurafenib, withdrawal of consent, and study termination by the sponsor |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| RO5185426 | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Any Adverse Event, Adverse Events With Severity, Adverse Events Leading to Discontinuation | An Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs will be graded according to the 'National Cancer Institute Common Terminology Criteria for Adverse Events' (NCI CTCAE, v4.0). However Laboratory data will be summarized by grade using the NCI CTCAE, v4.0 toxicity grade. | Up to 1 year |
| Number of Participants With Any Serious Adverse Event, Death and Cause of Death | Serious Adverse Event (SAEs) is defined as those events that were fatal or immediately life-threatening, and those events that resulted in hospitalization; prolonged an existing hospitalization; resulted in disability; or was a congenital anomaly. Number of participants who died and the cause of death are also recorded. | Up to 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Best Overall Response (Unconfirmed) | The best overall response (unconfirmed) is the best response recorded from the start of the treatment until disease progression/recurrence which was unconfirmed. Participants were assessed for best overall response by investigator as per 'Response Evaluation Criteria in Solid Tumors' (RECIST v1.1). | Up to 1 year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tucson | Arizona | 85724-5078 | United States | |||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24983357 | Derived | Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MA, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJ. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One. 2014 Jul 1;9(7):e101286. doi: 10.1371/journal.pone.0101286. eCollection 2014. |
Not provided
Not provided
Overall, 745 participants were screened during the study, of which 374 were enrolled to receive study treatment; the main reason for screen failure was negative cobas test, consent withdrawal, BRAF test not performed, patient died or progressed, and other unspecified reasons. Of 374 participants, 3 did not receive treatment after enrollment.
The study was conducted in 29 study sites in the United States (US). The study period was from 10 December 2010 to 24 October 2011.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Overall Trial | Participants received vemurafenib 960 milligram (mg) orally two times a day for up to one year. Participants were treated until disease progression, unmanageable toxicity most probably attributable to vemurafenib, withdrawal of consent, and study termination by the sponsor. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Number of Participants With Best Overall Response (Unconfirmed) by ECOG Performance | The best overall response recorded from the start of the treatment until disease progression/recurrence which was unconfirmed in patients with Eastern Cooperative Oncology Group (ECOG) performance status 2 or 3/0 or 1. Following are ECOG grades. 0: Fully active, perform all pre-disease activities without restriction. 1: Restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature. 2: Ambulatory, capable of selfcare, unable to carry out any work activities, up and about more than (>) 50% of waking hours. 3: Capable of limited selfcare, confined to bed or chair >50% of waking hours. 4: Completely disabled, not capable of any selfcare, totally confined to bed or chair. 5: Dead. This endpoint was tumor response category according to investigator assessment per RECIST v1.1 for efficacy assessment. The 'n' is number of participants with ECOG performance status in each criteria. | Up to 1 year |
| Number of Participants With Best Overall Response (Confirmed) | The best overall response (confirmed) is the best response recorded from the start of the treatment until disease progression/recurrence which was confirmed. Participants were assessed for best overall response by investigator as per RECIST v1.1. | Up to 1 year |
| Number of Participants With Best Overall Response (Confirmed) by ECOG Performance | The best overall response recorded from the start of the treatment until disease progression/recurrence which was confirmed in patients with Eastern Cooperative Oncology Group (ECOG) performance status 2 or 3/0 or 1. Following are ECOG grades. 0: Fully active, perform all pre-disease activities without restriction. 1: Restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature. 2: Ambulatory, capable of selfcare, unable to carry out any work activities, up and about more than (>) 50% of waking hours. 3: Capable of limited selfcare, confined to bed or chair >50% of waking hours. 4: Completely disabled, not capable of any selfcare, totally confined to bed or chair. 5: Dead. Participants were assessed for best overall response by investigator as per RECIST v1.1. The 'n' is number of participants with ECOG performance status in each criteria. | Up to 1 year |
| Mean Time to Complete Response/Partial Response | Mean time to Complete Response (CR)/Partial Response(PR) (confirmed or unconfirmed was assessed). Participants were assessed for best overall response by investigator as per RECIST v1.1. | Up to 1 year |
| Los Angeles |
| California |
| 90095 |
| United States |
| San Francisco | California | 94115 | United States |
| San Francisco | California | 94117 | United States |
| Santa Monica | California | 90025 | United States |
| Aurora | Colorado | 80045 | United States |
| New Haven | Connecticut | 06520-8063 | United States |
| Palm Harbor | Florida | 34684 | United States |
| Tampa | Florida | 33612-9497 | United States |
| Atlanta | Georgia | 30322 | United States |
| Park Ridge | Illinois | 60068 | United States |
| Boston | Massachusetts | 02114 | United States |
| Boston | Massachusetts | 02215 | United States |
| Detroit | Michigan | 48201 | United States |
| St Louis | Missouri | 63110 | United States |
| New York | New York | 10016 | United States |
| New York | New York | 10029 | United States |
| New York | New York | 10032 | United States |
| New York | New York | 10065 | United States |
| Cincinnati | Ohio | 45242 | United States |
| Oklahoma City | Oklahoma | 73104 | United States |
| Portland | Oregon | 97225 | United States |
| Philadelphia | Pennsylvania | 19104 | United States |
| Columbia | South Carolina | 29210 | United States |
| Nashville | Tennessee | 37203 | United States |
| Dallas | Texas | 75246 | United States |
| Richmond | Virginia | 23230 | United States |
| Seattle | Washington | 98195 | United States |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Safety population included all the participants who received at least one dose, or a partial dose of vemurafenib. Three participants who were enrolled did not receive vemurafenib hence not included in safety population.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Overall Trial | Participants received vemurafenib 960 mg orally two times a day for up to one year. Participants were treated until disease progression, unmanageable toxicity most probably attributable to vemurafenib, withdrawal of consent, and study termination by the sponsor. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| ||||||||||||||||||||||
| Age, Customized | Number | participants |
| |||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary | Number of Participants With Best Overall Response (Unconfirmed) | The best overall response (unconfirmed) is the best response recorded from the start of the treatment until disease progression/recurrence which was unconfirmed. Participants were assessed for best overall response by investigator as per 'Response Evaluation Criteria in Solid Tumors' (RECIST v1.1). | The efficacy population was defined as treated participants who had measurable disease at baseline and at least one post-baseline tumor assessment. | Posted | Number | participants | Up to 1 year |
|
|
| ||||||||||||||||||||||||||
| Secondary | Number of Participants With Best Overall Response (Unconfirmed) by ECOG Performance | The best overall response recorded from the start of the treatment until disease progression/recurrence which was unconfirmed in patients with Eastern Cooperative Oncology Group (ECOG) performance status 2 or 3/0 or 1. Following are ECOG grades. 0: Fully active, perform all pre-disease activities without restriction. 1: Restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature. 2: Ambulatory, capable of selfcare, unable to carry out any work activities, up and about more than (>) 50% of waking hours. 3: Capable of limited selfcare, confined to bed or chair >50% of waking hours. 4: Completely disabled, not capable of any selfcare, totally confined to bed or chair. 5: Dead. This endpoint was tumor response category according to investigator assessment per RECIST v1.1 for efficacy assessment. The 'n' is number of participants with ECOG performance status in each criteria. | The efficacy population was defined as treated patients who had measurable disease at baseline and at least one post-baseline tumor assessment. | Posted | Number | Participants | Up to 1 year |
| ||||||||||||||||||||||||||||
| Secondary | Number of Participants With Best Overall Response (Confirmed) | The best overall response (confirmed) is the best response recorded from the start of the treatment until disease progression/recurrence which was confirmed. Participants were assessed for best overall response by investigator as per RECIST v1.1. | The efficacy population was defined as treated participants who had measurable disease at baseline and at least one post-baseline tumor assessment. | Posted | Number | Participants | Up to 1 year |
|
| |||||||||||||||||||||||||||
| Secondary | Number of Participants With Best Overall Response (Confirmed) by ECOG Performance | The best overall response recorded from the start of the treatment until disease progression/recurrence which was confirmed in patients with Eastern Cooperative Oncology Group (ECOG) performance status 2 or 3/0 or 1. Following are ECOG grades. 0: Fully active, perform all pre-disease activities without restriction. 1: Restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature. 2: Ambulatory, capable of selfcare, unable to carry out any work activities, up and about more than (>) 50% of waking hours. 3: Capable of limited selfcare, confined to bed or chair >50% of waking hours. 4: Completely disabled, not capable of any selfcare, totally confined to bed or chair. 5: Dead. Participants were assessed for best overall response by investigator as per RECIST v1.1. The 'n' is number of participants with ECOG performance status in each criteria. | The efficacy population was defined as treated participants who had measurable disease at baseline and at least one post-baseline tumor assessment. | Posted | Number | Participants | Up to 1 year |
| ||||||||||||||||||||||||||||
| Secondary | Mean Time to Complete Response/Partial Response | Mean time to Complete Response (CR)/Partial Response(PR) (confirmed or unconfirmed was assessed). Participants were assessed for best overall response by investigator as per RECIST v1.1. | The efficacy population was defined as treated participants who had measurable disease at baseline and at least one post-baseline tumor assessment. | Posted | Mean | Standard Deviation | Months | Up to 1 year |
|
| ||||||||||||||||||||||||||
| Primary | Number of Participants With Any Adverse Event, Adverse Events With Severity, Adverse Events Leading to Discontinuation | An Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs will be graded according to the 'National Cancer Institute Common Terminology Criteria for Adverse Events' (NCI CTCAE, v4.0). However Laboratory data will be summarized by grade using the NCI CTCAE, v4.0 toxicity grade. | The safety population was defined as participants who received at least one dose, or a partial dose, of vemurafenib. | Posted | Number | participants | Up to 1 year |
|
| |||||||||||||||||||||||||||
| Primary | Number of Participants With Any Serious Adverse Event, Death and Cause of Death | Serious Adverse Event (SAEs) is defined as those events that were fatal or immediately life-threatening, and those events that resulted in hospitalization; prolonged an existing hospitalization; resulted in disability; or was a congenital anomaly. Number of participants who died and the cause of death are also recorded. | The safety population was defined as participants who received at least one dose, or a partial dose, of vemurafenib. | Posted | Number | participants | Up to 1 year |
|
|
Up to 1 Year
Serious adverse events and non-serious adverse events are reported in safety analysis set, which consists of all participants who received at least one dose of study medication and had a safety assessment performed post baseline.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Overall Trial | Participants received vemurafenib 960 mg orally two times a day for up to one year. Participants were treated until disease progression, unmanageable toxicity most probably attributable to vemurafenib, withdrawal of consent, and study termination by the sponsor | 83 | 371 | 308 | 371 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Vomiting | Gastrointestinal disorders | 15.0 | Systematic Assessment |
| |
| Abdominal Pain | Gastrointestinal disorders | 15.0 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | 15.0 | Systematic Assessment |
| |
| Ascites | Gastrointestinal disorders | 15.0 | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | 15.0 | Systematic Assessment |
| |
| Diverticular Perforation | Gastrointestinal disorders | 15.0 | Systematic Assessment |
| |
| Gastric Ulcer | Gastrointestinal disorders | 15.0 | Systematic Assessment |
| |
| Gastrointestinal Haemorrhage | Gastrointestinal disorders | 15.0 | Systematic Assessment |
| |
| Small Intestinal Obstruction | Gastrointestinal disorders | 15.0 | Systematic Assessment |
| |
| Cellulitis | Infections and infestations | 15.0 | Systematic Assessment |
| |
| Urinary Tract Infection | Infections and infestations | 15.0 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | 15.0 | Systematic Assessment |
| |
| Bacterial Infection | Infections and infestations | 15.0 | Systematic Assessment |
| |
| Clostridial infection | Infections and infestations | 15.0 | Systematic Assessment |
| |
| Sepsis | Infections and infestations | 15.0 | Systematic Assessment |
| |
| Pyrexia | General disorders | 15.0 | Systematic Assessment |
| |
| Death | General disorders | 15.0 | Systematic Assessment |
| |
| Asthenia | General disorders | 15.0 | Systematic Assessment |
| |
| Chest Pain | General disorders | 15.0 | Systematic Assessment |
| |
| Drug Withdrawal Syndrome | General disorders | 15.0 | Systematic Assessment |
| |
| Fatigue | General disorders | 15.0 | Systematic Assessment |
| |
| Multi-organ failure | General disorders | 15.0 | Systematic Assessment |
| |
| Pain | General disorders | 15.0 | Systematic Assessment |
| |
| Convulsion | Nervous system disorders | 15.0 | Systematic Assessment |
| |
| Headache | Nervous system disorders | 15.0 | Systematic Assessment |
| |
| Cerebral haemorrhage | Nervous system disorders | 15.0 | Systematic Assessment |
| |
| Hydrocephalus | Nervous system disorders | 15.0 | Systematic Assessment |
| |
| Lethargy | Nervous system disorders | 15.0 | Systematic Assessment |
| |
| Lumbar Radiculopathy | Nervous system disorders | 15.0 | Systematic Assessment |
| |
| Paraesthesia | Nervous system disorders | 15.0 | Systematic Assessment |
| |
| Spinal Cord Compression | Nervous system disorders | 15.0 | Systematic Assessment |
| |
| Dehydration | Metabolism and nutrition disorders | 15.0 | Systematic Assessment |
| |
| Hyperkalaemia | Metabolism and nutrition disorders | 15.0 | Systematic Assessment |
| |
| Failure To Thrive | Metabolism and nutrition disorders | 15.0 | Systematic Assessment |
| |
| Hypokalaemia | Metabolism and nutrition disorders | 15.0 | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | 15.0 | Systematic Assessment |
| |
| Respiratory Failure | Respiratory, thoracic and mediastinal disorders | 15.0 | Systematic Assessment |
| |
| Pulmonary Embolism | Respiratory, thoracic and mediastinal disorders | 15.0 | Systematic Assessment |
| |
| Pulmonary Haemorrhage | Respiratory, thoracic and mediastinal disorders | 15.0 | Systematic Assessment |
| |
| Electrocardiogram Qt Prolonged | Investigations | 15.0 | Systematic Assessment |
| |
| Blood Bilirubin Increased | Investigations | 15.0 | Systematic Assessment |
| |
| Blood Creatine Phosphokinase Increased | Investigations | 15.0 | Systematic Assessment |
| |
| Blood Uric Acid Increased | Investigations | 15.0 | Systematic Assessment |
| |
| Neutrophil count decreased | Investigations | 15.0 | Systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | 15.0 | Systematic Assessment |
| |
| Neck Pain | Musculoskeletal and connective tissue disorders | 15.0 | Systematic Assessment |
| |
| Back Pain | Musculoskeletal and connective tissue disorders | 15.0 | Systematic Assessment |
| |
| Musculoskeletal Pain | Musculoskeletal and connective tissue disorders | 15.0 | Systematic Assessment |
| |
| Confusional State | Psychiatric disorders | 15.0 | Systematic Assessment |
| |
| Mental Status Changes | Psychiatric disorders | 15.0 | Systematic Assessment |
| |
| Paranoia | Psychiatric disorders | 15.0 | Systematic Assessment |
| |
| Anaemia | Blood and lymphatic system disorders | 15.0 | Systematic Assessment |
| |
| Lymphopenia | Blood and lymphatic system disorders | 15.0 | Systematic Assessment |
| |
| Neutropenia | Blood and lymphatic system disorders | 15.0 | Systematic Assessment |
| |
| Angioedema | Skin and subcutaneous tissue disorders | 15.0 | Systematic Assessment |
| |
| Dermatitis | Skin and subcutaneous tissue disorders | 15.0 | Systematic Assessment |
| |
| Photosensitivity Reaction | Skin and subcutaneous tissue disorders | 15.0 | Systematic Assessment |
| |
| Rash | Skin and subcutaneous tissue disorders | 15.0 | Systematic Assessment |
| |
| Rash Maculo-Papular | Skin and subcutaneous tissue disorders | 15.0 | Systematic Assessment |
| |
| Atrial Flutter | Cardiac disorders | 15.0 | Systematic Assessment |
| |
| Cardiac failure congestive | Cardiac disorders | 15.0 | Systematic Assessment |
| |
| Pericardial Effusion | Cardiac disorders | 15.0 | Systematic Assessment |
| |
| Procedural pain | Injury, poisoning and procedural complications | 15.0 | Systematic Assessment |
| |
| Spinal compression fracture | Injury, poisoning and procedural complications | 15.0 | Systematic Assessment |
| |
| Toxicity to various agents | Injury, poisoning and procedural complications | 15.0 | Systematic Assessment |
| |
| Renal Colic | Renal and urinary disorders | 15.0 | Systematic Assessment |
| |
| Renal Failure | Renal and urinary disorders | 15.0 | Systematic Assessment |
| |
| Renal Failure Acute | Renal and urinary disorders | 15.0 | Systematic Assessment |
| |
| Pupils unequal | Eye disorders | 15.0 | Systematic Assessment |
| |
| Uveitis | Eye disorders | 15.0 | Systematic Assessment |
| |
| Hyperbilirubinaemia | Hepatobiliary disorders | 15.0 | Systematic Assessment |
| |
| Metastases To Central Nervous System | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 15.0 | Systematic Assessment |
| |
| Female genital tract fistula | Reproductive system and breast disorders | 15.0 | Systematic Assessment |
| |
| Deep Vein Thrombosis | Vascular disorders | 15.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Rash | Skin and subcutaneous tissue disorders | 15.0 | Systematic Assessment |
| |
| Photosensitivity Reaction | Skin and subcutaneous tissue disorders | 15.0 | Systematic Assessment |
| |
| Alopecia | Skin and subcutaneous tissue disorders | 15.0 | Systematic Assessment |
| |
| Hyperkeratosis | Skin and subcutaneous tissue disorders | 15.0 | Systematic Assessment |
| |
| Dry Skin | Skin and subcutaneous tissue disorders | 15.0 | Systematic Assessment |
| |
| Palmar-plantar erythrodysaesthesia syndrome | Skin and subcutaneous tissue disorders | 15.0 | Systematic Assessment |
| |
| Pruritus | Skin and subcutaneous tissue disorders | 15.0 | Systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | 15.0 | Systematic Assessment |
| |
| Myalgia | Musculoskeletal and connective tissue disorders | 15.0 | Systematic Assessment |
| |
| Pain In Extremity | Musculoskeletal and connective tissue disorders | 15.0 | Systematic Assessment |
| |
| Fatigue | General disorders | 15.0 | Systematic Assessment |
| |
| Oedema Peripheral | General disorders | 15.0 | Systematic Assessment |
| |
| Pyrexia | General disorders | 15.0 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | 15.0 | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | 15.0 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | 15.0 | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | 15.0 | Systematic Assessment |
| |
| Sunburn | Injury, poisoning and procedural complications | 15.0 | Systematic Assessment |
| |
| Squamous Cell Carcinoma Of Skin | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 15.0 | Systematic Assessment |
| |
| Skin Papilloma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 15.0 | Systematic Assessment |
| |
| Decreased Appetite | Metabolism and nutrition disorders | 15.0 | Systematic Assessment |
| |
| Headache | Nervous system disorders | 15.0 | Systematic Assessment |
| |
| Weight decreased | Investigations | 15.0 | Systematic Assessment |
|
The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Roche Trial Information Hotline | F. Hoffmann-La Roche AG | +41 616878333 | global.trial_information@roche.com |
| ID | Term |
|---|---|
| D008545 | Melanoma |
| ID | Term |
|---|---|
| D018358 | Neuroendocrine Tumors |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009380 | Neoplasms, Nerve Tissue |
| D018326 | Nevi and Melanomas |
| D012878 | Skin Neoplasms |
| D009371 | Neoplasms by Site |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| From 65 - 84 years |
|
| Over 85 years |
|
| Units | Counts |
|---|
| Participants |
|
|
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
|
|
|
|